Amgen Inc (BUE:AMGN)
ARS 10425 -25 (-0.24%) Market Cap: 153.50 Til Enterprise Value: 205.37 Til PE Ratio: 36.22 PB Ratio: 20.20 GF Score: 57/100

Amgen Inc at Wells Fargo Healthcare Conference Transcript

Sep 06, 2023 / 01:30PM GMT
Release Date Price: ARS18965.5 (-1.71%)
Mohit Bansal
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst

Thank you very much for joining us today. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo. And I have Peter Griffith, the CFO of the company; and Arvind Sood, the greatest of all times. So thank you both for joining us today.

I'll turn it over to Peter for opening remarks here.

Peter H. Griffith
Amgen Inc. - Executive VP & CFO

Mohit, thank you very much. And actually, this is Murdo Gordon (inaudible). But good morning, and we're so glad to be here. Thanks for inviting us. As we always do at Amgen, let's start with patients and our mission to serve patients through discovering, developing, manufacturing and distributing first-in-class and best-in-class medicines to patients with grievous and serious illness all over the world.

We're creating value for patients, staff and shareholders, and are well positioned on any number of fronts that deliver long-term growth. We're driving a successful integration beginning off an early

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot